Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.

ABSTRACT: Over the past 40 years, the 5-years-overall survival rate of pediatric cancer reached 75-80%, and for acute lymphoblastic leukemia (ALL), exceeded 90%. Leukemia continues to be a major cause of mortality and morbidity for specific patient populations, including infants, adolescents, and patients with high-risk genetic abnormalities. The future of leukemia treatment needs to count better on molecular therapies as well as immune and cellular therapy. Advances in the scientific interface have led naturally to advances in the treatment of childhood cancer. These discoveries have involved the recognition of the importance of chromosomal abnormalities, the amplification of the oncogenes, the aberration of tumor suppressor genes, as well as the dysregulation of cellular signaling and cell cycle c

SUBMITTER: Ivanov AV 

PROVIDER: S-EPMC10003692 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature